Suppr超能文献

局部晚期横结肠癌新辅助三联化疗后的病理完全缓解

A pathological complete response after neoadjuvant triplet chemotherapy for locally advanced transverse colon cancer.

作者信息

Tominaga Tetsuro, Nonaka Takashi, Tabata Kazuhiro, Sawai Terumitsu, Nagayasu Takeshi

机构信息

Departments of Surgical Oncology, Nagasaki University Graduate School of Biomedical Science, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.

Departments of Surgical Oncology, Nagasaki University Graduate School of Biomedical Science, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.

出版信息

Int J Surg Case Rep. 2020;72:127-132. doi: 10.1016/j.ijscr.2020.05.077. Epub 2020 Jun 6.

Abstract

INTRODUCTION

Perioperative chemotherapy could improve oncological outcomes for patients with advanced colon cancer. However, the effectiveness of triplet chemotherapy in the neoadjuvant setting is still unknown.

PRESENTATION OF CASE

A 61-year-old man was referred to our hospital due to abdominal distention. Abdominal computed tomography showed a huge, 18-cm mass in the right upper abdomen. Biopsy showed well-differentiated adenocarcinoma. Locally advanced transverse colon cancer T4b N2a M0 Stage IIIC was diagnosed. Considering the extensive invasion to surrounding organs and difficulties in achieving margin-negative surgery, an emergency ileostomy was performed first. Then, neoadjuvant chemotherapy (NAC) consisting of a combination of 5-fluorouracil (5-FU), oxaliplatin, irinotecan, and leucovorin (FOLFOXIRI) was planned, followed by primary tumor resection. After 6 courses of treatment, the primary tumor shrank remarkably. Finally, laparoscopic radical extended right hemi-colectomy was performed. There were no residual tumor cells in resected specimens, including the primary tumor and surrounding lymph nodes. The pathological diagnosis was complete response.

CONCLUSION

A case of pathological complete response after neoadjuvant treatment followed by radical resection was reported. Further research is needed to confirm the appropriate indications for neoadjuvant FOLFOXIRI therapy for patients with LACC.

摘要

引言

围手术期化疗可改善晚期结肠癌患者的肿瘤学结局。然而,三联化疗在新辅助治疗中的有效性仍不明确。

病例介绍

一名61岁男性因腹胀转诊至我院。腹部计算机断层扫描显示右上腹有一个18厘米的巨大肿块。活检显示为高分化腺癌。诊断为局部晚期横结肠癌T4b N2a M0 III期C。考虑到对周围器官的广泛侵犯以及实现切缘阴性手术的困难,首先进行了急诊回肠造口术。然后,计划进行由5-氟尿嘧啶(5-FU)、奥沙利铂、伊立替康和亚叶酸钙(FOLFOXIRI)联合组成的新辅助化疗(NAC),随后进行原发肿瘤切除。经过6个疗程的治疗,原发肿瘤明显缩小。最后,进行了腹腔镜根治性扩大右半结肠切除术。切除标本,包括原发肿瘤和周围淋巴结,均无残留肿瘤细胞。病理诊断为完全缓解。

结论

报告了一例新辅助治疗后根治性切除达到病理完全缓解的病例。需要进一步研究以确定LACC患者新辅助FOLFOXIRI治疗的合适指征。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f60/7298320/3f7215b4e9ed/gr1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验